Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common shares from the full exercise of the underwriters’ option to purchase additional common shares.

The common shares are listed on the NASDAQ Global Market under the symbol “CYNA” and on the Toronto Stock Exchange under the symbol “CTH.”   

Headquartered in Toronto, Ontario, Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize APL-130277, a Phase 3, fast-acting, easy-to-use sublingual thin film that combats OFF episodes associated with Parkinson’s Disease.    

The Davis Polk corporate team included partner Deanna L. Kirkpatrick, counsel Alain Kuyumjian and associates Milson C. Yu and Elyka Anvari. The tax team included counsel Gregory T. Hannibal and associates Adam B. Perry and Caitlin Piper. The intellectual property team included partner Frank J. Azzopardi and associates Pritesh P. Shah and Natalie A. Thomas. Members of the Davis Polk team are based in the New York office.   

Copy link to share post